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Abstract
Background: A novel influenza virus, subtype H7N9, circulated through China in 2013–2014. Its higher rates of human
infection in a wide range of locations within China and the associated increased likelihood of human-to-human
transmission have caused global concern. Recombinant subunit vaccines provide safe and targeted protection against
viral infections. However, the protective efficacy of recombinant subunit vaccines tends to be less potent than vaccines
made from whole viruses. Studies have shown that bacterial flagellin has strong adjuvant activity and induces protective
immune responses.
Results: In this study, we used overlap-PCR to generate an H7N9 influenza recombinant subunit vaccine that fused the
globular head domain (HA1-2, aa 62–284) of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand,
Salmonella typhimurium flagellin (fliC). The resulting fusion protein, HA1-2-fliC, was efficiently expressed in an Escherichia
coli prokaryotic expression system, and Western blotting and TLR5-stimulating activity analysis confirmed that the
HA1-2-fliC moiety could be faithfully refolded to take on the native HA and fliC conformations. In a C3H/HeJ mouse
model of intraperitoneal vaccination, the fusion protein elicited significant and robust HA1-2-specific serum IgG titers,
maintaining high levels for at least 3 months in the vaccinated animals, and induced similar levels of HA1-2-specific
IgG1 and IgG2a that were detectable 12 days after the third immunization. HA1-2-fliC was also found to be capable
of triggering the production of neutralizing antibodies, as assessed by measuring hemagglutination inhibition titers.
Conclusions: We conclude that immunization with HA1-2-fliC induces potent HA1-2-specific responses, offering
significant promise for the development of a successful recombinant subunit vaccine for avian influenza A (H7N9).
Background
Avian-origin influenza A (H7N9) virus emerged as a
human pathogen in China in spring 2013 and, as of
October 2014, it caused 453 human cases and 175
deaths [1]. At this rate, it will soon match or surpass
the burden of avian influenza A (H5N1) (676 cases,
as of December 2014) [2]. Cases of H7N9 are cur-
rently accumulating at a pace that is five times faster
than avian influenza A (H5N1). The epidemiology of
this outbreak has implied that live bird markets are
the source of human infections. Although shutting down
live poultry markets resulted in an immediate reduction
in cases [3], the outbreak of human infection with influ-
enza H7N9 virus has re-emphasized the importance of
making faster and more effective influenza vaccines than
those that are currently available.
At present, live-attenuated, inactivated whole virus or
split vaccines produced in embryonated hens’ eggs are
used to control influenza. However, production of these
types of H7N9 influenza vaccines often has several
hurdles [4]. Some laboratories have studied the live-
attenuated H7N9 virus vaccine candidate [5] and other
H7 subtype virus vaccines [6, 7] for their ability to
protect from H7N9 virus infection.
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Subunit vaccines, in contrast to live-attenuated or inac-
tivated whole virus vaccines, include only specific antigens
that stimulate immune responses. Recombinant subunit
vaccine technology is a promising approach to develop
safe vaccines capable of inducing specific immune re-
sponses [8]. However, compared with live-attenuated or
inactivated whole virus vaccines, subunit vaccines have
low immune-stimulating capacity. It is now well estab-
lished that linkage of Toll-like receptor (TLR) ligands and
vaccine antigens enhances the immunopotency of the
linked antigen [9].
Flagellin, a TLR5 ligand, induces downstream signaling in
a MyD88-dependent manner [10]. Studies from several
groups have established that recognition of flagellin by the
innate immune system leads to cytokine production and
dendritic cell (DC) activation [11–13]. The adjuvant effect
of flagellin has been demonstrated in a variety of pathogen
models, including influenza [14, 15], Yersinia pestis [16],
and Pseudomonas aeruginosa [17]. These protective re-
sponses characteristically exhibit remarkably high titers of
antigen-specific IgG.
Hemagglutinin (HA), the surface glycoprotein of influ-
enza virus, has been the key protective antigen in sea-
sonal influenza vaccine studies for 40 years [14]. The
overall predicted HA protein structure of A/Hangzhou/
1/2013 (H7N9), closely resembles other reported HA
structures [18]. The HA globular head domain contains
the cell surface receptor binding site and the majority of
the neutralizing antibody epitopes [19, 20]. Studies have
shown that HA1-2 (residues 62–284) on the HA globu-
lar head domain encompasses the neutralizing epitopes
of the globular head and also contains the structural
elements necessary for efficient folding to correctly dis-
play these epitopes after recombinant protein expression
in Escherichia coli [14].
In this study, we hypothesized that Salmonella
typhimurium flagellin (fliC) could be a stable fusion
partner for HA1-2 and that the resulting fusion pro-
tein would be efficiently manufactured using an E. coli
prokaryotic expression system and induce efficient
immune response. We constructed a fusion protein by
fusing HA1-2 with the N-terminus of fliC by physical
linkers and then tested the resulting protein for TLR5-
specific activity and immunoreactivity. Last, we de-
monstrated that the mice immunized intraperitoneally
with the HA1-2-fliC fusion protein developed significantly
higher HA1-2-specific serum IgG and hemagglutination
inhibition (HAI) titers compared with the mice injected
with HA1-2 alone.
Methods
Construction of recombinant plasmids
Viral RNA was extracted from the inactivated avian
influenza A/chicken/Jiangsu/CZT4/2013 (H7N9) virus
(Animal Infectious Disease Laboratory, School of Veter-
inary Medicine, Yangzhou University, Yangzhou, China)
using TRIzol reagent (Invitrogen, USA), and viral cDNA
was synthesized using Oligo dT primer (Takara, Dalian,
China) according to the manufacturer’s instructions. Based
on the HA sequence of influenza A virus (A/Hangzhou/1/
2013(H7N9)) [GenBank: KC853766.1] and the sequence of
S. typhimurium flagellin (fliC) [GenBank: CP001363.1],
three pairs of primers were designed for amplifying the
objective fragments (Table 1). The HA1-2 gene fragment
was amplified from cDNA by PCR with forward primer
HA1-2-F1 and reverse primer HA1-2-R1. Similarly, the
HA1-2 fragment of the fusion gene was amplified using
primers HA1-2-F2 and HA1-2-R2, and the full-length fliC
gene was amplified using primers fliC-F and fliC-R from
the template plasmid pET30a-fliC-WT [21]. Then, the
HA1-2 gene was fused directly to the N-terminus of
the fliC by overlap-PCR from the PCR products (HA1-
2 and fliC gene) with forward primer HA1-2-F2 and
reverse primer fliC-R. Both HA1-2 and HA1-2-fliC
PCR products were cloned into the pCold vectors
(Takara, Dalian, China), after being digested by SacI/
HindIII or EcoRI/XbaI in advance, generating the con-
structs pCold-HA1-2 and pCold-HA1-2-fliC, respect-
ively. The resulting constructs were confirmed via DNA
sequencing by Genscript (Nanjing, China).
Expression and characterization of recombinant proteins
The recombinant proteins HA1-2 and HA1-2-fliC with a
His-tag at the end of each of their N-terminuses were
expressed in E. coli using a Cold Shock Expression System
with pCold DNA (Takara, Dalian, China) according to the
manufacturer’s instructions. Cell lysates were evaluated by
SDS-PAGE. Soluble HA1-2-fliC was purified with a His•
Bind Purification Kit (Novagen, USA), according to the
manufacturer’s instructions. The purification of HA1-2
inclusion bodies was also performed with a His•Bind Purifi-
cation Kit under the condition of 6 M urea, followed by
dialysis in PBS. The purified proteins were resolved via
SDS-PAGE, and Western blotting was performed using
mouse polyclonal antibody specific for fliC (anti-fliC) or
inactivated avian influenza A (H7N9) virus (anti-H7N9
virus).
TLR5 activity of the fusion protein
TLR5 activity of the HA1-2-fliC fusion protein was evalu-
ated by measuring the induction of IL-8 production by
HEK 293-mTLR5 cells (Invivogen, USA). Cells were
cultured in 96-well microtiter plates at a seeding density
of 5 × 104 cells in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10 % fetal calf serum (FCS)
and antibiotics. The next day, cells were treated for 5 h
with 100 ng/ml of the fusion and control proteins. At the
completion of the assay, supernatants were harvested, and
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IL-8 expression was evaluated by an enzyme-linked im-
munosorbent assay (ELISA), using Human IL-8 Ready-
SET-Go!® ELISA Set (eBioscience, USA). Endotoxin was
removed from the proteins HA1-2 and HA1-2-fliC by
using the ProteoSpin™ Endotoxin Removal Kit Maxi for
protein & peptides (Norgen, Canada) according to the
manufacturer’s instructions, and the residual endotoxin
level was measured using a chromogenic endpoint tachy-
pleus amebocyte lysate (CE TAL) assay kit (Chinese
Horseshoe Crab Reagent Manufactory Co., Ltd. China)
according to the manufacturer’s instructions.
Vaccination and blood sample collection schedule
Six-week-old female C3H/HeJ mice were purchased from
the Biomedical Research Institute of Nanjing University,
Nanjing, China. All animals were housed in isolators and
fed a pathogen-free diet and water. The procedures de-
scribed in this study were approved by the Committee on
the Ethics of Animal Experiments of Yangzhou University,
Yangzhou, China. Groups of C3H/HeJ mice (n = 6) were
vaccinated intraperitoneally (i.p.) with doses of 15 μg HA1-
2, 50 μg HA1-2-fliC (containing 15 μg HA1-2, according to
the molecular weight), or PBS on days 0, 14, and 28. The
animals were bled 12 days following the second and third
immunizations (on days 26 and 40). Serum samples were
subjected to hemagglutination inhibition assays and assays
to determine the titers of HA1-2-specific IgG and its
subtypes, IgG1 and IgG2a. Over the course of this schedule,
the animals were bled for about 3 months at 12-day inter-
vals, and serum samples were used to determine the time
course of HA1-2-specific serum IgG responses (Fig. 1).
ELISA
Serum titers of antigen-specific IgG, IgG1and IgG2a
were determined by an indirect ELISA, as described pre-
viously [22]. Briefly, 96-well plates were coated with
1.5 μg/ml GST-tagged HA1-2 antigen overnight at 4 °C.
After washing and blocking, serial dilutions of antiserum
were added in triplicate and incubated for 2 h at 37 °C.
Horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG, IgG1, or IgG2a (Invitrogen, USA) were in-
cubated for 1 h at 37 °C as the secondary antibody. 3, 3′,
5, 5′-tetramethybenzidine was used as a substrate to
estimate the enzymatic activity. The reaction was stopped
with 2 M H2SO4, and the absorbance was measured at
450 nm using a Microplate Reader (Bio-Tek EL 680,
USA).
HAI assay
All HAI assays were performed in V-bottomed 96-well
plates. Serum samples collected from mice were treated
with receptor destroying enzyme (RDE) II overnight, heat-
inactivated (56 °C, 30 min), diluted in 96-well V-bottomed
microtiter plates, and incubated with 4 HA units (HAU)
of inactivated avian influenza A (H7N9) virus for 30 min
at room temperature. After that, 1 % chicken erythrocytes
were added, mixed briefly, and incubated for 30 min at
room temperature. The highest dilution of serum that
inhibited hemagglutination was considered the HAI titer.
Statistical analysis
All results are expressed as the mean ± SEM unless other-
wise stated. Serum titers of HA1-2-specific IgG, IgG1, and
IgG2a were analyzed using log10 transformed data, and
HAI serum titers were analyzed using log2 transformed
data. The statistical significance between two groups was
analyzed using an unpaired Student’s t-test with GraphPad
Software 5.0 (San Diego, CA). p < 0.05 was considered sta-
tistically significant.
Table 1 Polymerase chain reaction primers used in this study
Primers Sequence Restricted site
HA1-2-F1 5′-CCCGAGCTCAAAGGGAAAAGGACAGTTGACC-3′ SacI
HA1-2-R1 5′-CCCAAGCTTGGCATCAACCTGTACT-3′ Hind III
HA1-2-F2 5′-CCGGAATTCAAAGGGAAAAGGACAGTTGACC-3′ EcoRI
HA1-2-R2 5′-CACCTCCGCTTCCACCTCCACCGGCATCAACCTGTACT-3′ (Gly4Ser)3
fliC-F 5′-AGGTGGAAGCGGAGGTGGTGGAAGCATGGCACAAGT CATTAATA-3′ (Gly4Ser)3
fliC-R 5′-CCGTCTAGATTAACGCAGTAAAGAGAGGACG-3′ XbaI
Fig. 1 Vaccination and blood sample collection schedule. Groups of
C3H/HeJ mice (n = 6) were vaccinated i.p. with three doses of HA1-2,
HA1-2-fliC, or PBS on days 0, 14, and 28. The animals were bled on
days 26 and 40, following the second and third immunization. In
total, the animals were bled for about 3 months (84 days) at 12-day
intervals, and the resulting serum samples were used to determine
the serum antibody responses over time
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Results
Expression and characterization of the recombinant
proteins
To create a fusion protein of HA1-2 and fliC, a fragment
containing the HA1-2 gene fused to the N-terminus of fliC
gene was designed (Fig. 2). The HA1-2-fliC and HA1-2
genes were cloned into pCold vectors to add a His-tag to
each target protein at the N-terminus. The resulting pro-
teins were successfully expressed in E. coli BL21, strain DE3
(Fig. 3a and b). Subsequent purification of HA1-2 and
HA1-2-fliC by His-tag affinity chromatography produced
proteins with the expected molecular weights of 26 kDa
and 82 kDa, respectively (Fig. 3c). The immunoreactivity of
the purified HA1-2-fliC was confirmed by Western blotting
using anti-fliC or anti-H7N9 virus polyclonal antibodies
(Fig. 4a and b). Similarly, purified HA1-2 was also analyzed
by Western blotting using an anti-H7N9 virus polyclonal
antibody (Fig. 4c).
TLR5 activity of the fusion protein
The ability of the fusion protein to activate TLR5 was
assessed using an in vitro assay. HA1-2-fliC induced a
significantly stronger IL-8 secretion (about 2,265 pg/ml)
than the HA1-2 control (99 pg/ml) (p < 0.001), and a
slightly lower IL-8 level than the positive control (about
3,226 pg/ml) (Fig. 5). To exclude the possibility that our
results were due to contamination by endotoxin in the IL-8
assay, the endotoxin level was tested, and it was determined
to be less than 0.01 EU/μg.
Immunogenicity of the recombinant proteins
Humoral immune responses induced by i.p. immunization
with the purified proteins were assessed by measuring the
IgG titers in the serum of vaccinated mice via an indirect
ELISA. Each group of C3H/HeJ mice was bled on days 26
and 40. HA1-2-fliC induced significantly stronger (p < 0.05)
HA1-2-specific IgG responses than HA1-2 or PBS, particu-
larly on day 40 (12 days after the third immunization). The
HA1-2-specific IgG titers induced by HA1-2-fliC after the
third immunization were about 4-fold higher than those
following the second immunization (Fig. 6a). Additionally,
immunization with HA1-2-fliC induced significantly
higher IgG1 (p < 0.05) and IgG2a (p < 0.01) titers than
immunization with HA1-2 or PBS. The IgG1 and
IgG2a average titers of HA1-2-fliC vaccinated mice
were 5.1 × 104 and 3.8 × 104, respectively, and these
amounts are not significantly different from one an-
other (Fig. 6b). These data indicate that vaccination
with HA1-2-fliC induced a relatively balanced IgG1
and IgG2a response.
A standard HAI assay was conducted to test the ability of
HA1-2-fliC to generate HAI antibodies. HAI antibody titers
were measured at 12 days after the third vaccination for
each group. The HA1-2-fliC group had significantly higher
HAI antibody titers than the HA1-2 (p < 0.001) or PBS
groups (Fig. 6c).
The longevity of HA1-2-specific serum IgG
To monitor the longevity of HA1-2-specific IgG antibodies
induced by the HA1-2-fliC protein in mice, the animals
were bled for about 3 months (84 days) at 12-day intervals
after the third immunization, and ELISAs were performed
on the serum samples to determine the serum titers. We
analyzed the time course of HA1-2-specific antibodies
induced by the HA1-2 and HA1-2-fliC proteins for 84 days
(Fig. 6d). The IgG titers in the HA1-2-fliC group reached
the highest levels on day 12 post-immunization, and then
fell slightly over the next 3 months. HA1-2-fliC induced
approximately 5–18 fold higher IgG titers than HA1-2 over
the different time points. Importantly, the HA1-2-specific
IgG titers remained high, even on day 84, suggesting that
HA1-2-fliC vaccination elicited robust HA1-2-specific
serum IgG titers that lasted for at least 3 months in mice.
Discussion
Expression of proteins in a prokaryotic system such as E.
coli could be substantially less expensive and allow for a
more rapid production of vaccines compared with conven-
tional methods [23]. Previously, improvements in influenza
vaccine production by the industry have focused on cell
culture. The cell culture-based approach alleviates the
significant manufacturing issues associated with egg-based
manufacturing, but it does not improve production effi-
ciency [14]. Recent data show that the glycosylation pattern
of HA does not impact the antibody response, suggesting
that glycosylation is not required for appropriate folding of
the molecule [24]. That finding is supported by our study,
which demonstrates that the HA1-2-fliC protein can be
successfully and efficiently expressed using an E. coli pro-
karyotic system (Fig. 3), and it elicits a robust antibody
response (Fig. 6).
Early vaccine formats fused the HA globular head to the
C-terminus of flagellin, replaced domain 3 of flagellin, or
placed one copy of the HA head at the C-terminus while
Fig. 2 Schematic for the construction of HA1-2-fliC. The cDNA sequence
encoding residues 62–284 of avian influenza A (H7N9) virus HA1-2 was
cloned for expression in E. coli. Meanwhile, the HA1-2 gene was further
fused to the N-terminus of the fliC gene to form HA1-2-fliC by a linker of
flexible peptide (Gly4Ser)3
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using a second copy to replace domain 3 [25]. Importantly,
the vaccine format not only affects the immunogenicity of
the vaccine antigen, it also affects the safety of the vaccine
in preclinical models [26]. Delaney et al. have found that
replacement of the hypervariable region of flagellin with
the vaccinia virus antigen L1R results in a vaccine that does
not generate antibody against native L1R. However, if L1R
is fused at the N-terminus of flagellin, antibody can be gen-
erated against native L1R [27]. Therefore, in this study, we
extended the flagellin-based vaccine format by fusing the
HA1-2 antigen to the N-terminus of flagellin. SDS-PAGE
analysis confirmed that the fusion protein HA1-2-fliC was
efficiently expressed in an E. coli expression system (Fig. 3a
and b). Additionally, the immunoreactivity of HA1-2-fliC
was confirmed via Western blotting using anti-fliC or anti-
H7N9 virus polyclonal antibodies (Fig. 4a and b), suggesting
that the HA1-2 and fliC moieties of the fusion protein are
faithfully refolded to take on the native conformations of
the parent two proteins.
Based on the literature, interaction of fliC with TLR5
leads to the secretion of pro-inflammatory cytokines,
such as IL-8, in epithelial cells [28]. In our study, TLR5-
dependent IL-8 secretion was induced by the HA1-2-
fliC fusion protein, suggesting that it stimulates potent
TLR5 signaling (Fig. 5). This finding is similar to that
from a recent study showing that the fusion protein fla-
gellin β-defensin-3 (FBD3) was also recognized by TLR5
expressed on target cells and stimulated the secretion of
Fig. 3 Protein expression and purification. a Expression of HA1-2. Lanes: M, protein marker; 1, product of BL21(DE3)(pCold) induced by IPTG; 2,
product of BL21(DE3)(pCold-HA1-2) not induced; 3, lysate supernatant of BL21(DE3)(pCold-HA1-2) induced by IPTG; 4, inclusion bodies of
BL21(DE3)(pCold-HA1-2) induced by IPTG. b Expression of HA1-2-fliC. Lanes: M, protein marker; 1, product of BL21(DE3)(pCold) induced by IPTG; 2,
product of BL21(DE3)(pCold-HA1-2-fliC) not induced; 3, lysate supernatant of BL21(DE3)(pCold-HA1-2-fliC) induced by IPTG; 4, inclusion bodies of
BL21(DE3)(pCold-HA1-2-fliC) induced by IPTG. c Protein purification. Lanes: M, protein marker; 1, HA1-2; 2, HA1-2-fliC
Fig. 4 Western blotting analyses. a HA1-2-fliC fusion protein was
detected using an anti-fliC polyclonal antibody. b HA1-2-fliC fusion
protein was detected using an anti-influenza A (H7N9) virus (anti-
H7N9 virus) polyclonal antibody. c HA1-2 protein was detected using
an anti-influenza A (H7N9) virus (anti-H7N9 virus) polyclonal antibody
Fig. 5 TLR5 activity of the fusion protein. Each of the proteins was
tested for TLR5 activity using HEK-293-mTLR5 cells. HA1-2-fliC was
compared to HA1-2 alone, using 100 ng/ml of each, and flagellin
(Enzo Life Sciences, USA) was used as a positive control. Data are
presented as mean ± SEM of IL-8 (pg/ml); *p < 0.05, **p < 0.01,
*** p < 0.001
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IL-8 [29]. These results suggest that the protein made
from the C-terminal HA1-2 fused with the N-terminal
fliC retains its TLR5 binding capacity.
Researchers have previously demonstrated the excellent
immunogenicity and efficacy of the vaccine platform (the
physical linkage of vaccine antigens to flagellin) when
applied to either seasonal H1N1 or highly pathogenic avian
influenza H5N1 in animal models [14, 15]. In these studies,
the fusion proteins elicited remarkably high antigen-specific
IgG and protective HAI titers, which protected mice
against disease and death in a lethal challenge model. In
our study, HA1-2-fliC also induced significant and robust
HA1-2-specific IgG responses, particularly on day 12 after
the final immunization, with a mean of 4.8 × 104 (Fig. 6a).
Thus, presentation of HA1-2 in the context of a flagellin fu-
sion protein significantly enhances the potency of HA1-2 as
an immunogen. Our results are consistent with the findings
that flagellin-L1R and flagellin-B5R fusion proteins are ef-
fective in eliciting immune responses against vaccinia virus
[27] and that flagellin-containing VLPs (containing A/PR8/
34(H1N1) HA, matrix protein (M1)) elicited higher specific
IgG responses than standard HA and M1 VLPs [30].
Some studies [31, 32] reported that co-delivery of fla-
gellin with an antigen resulted in Th2 responses in vivo.
However, another study suggested that co-immunization
of flagellin with inactivated foot-and-mouth disease virus
(FMDV) antigen induced Th1 polarization of the immune
system [33]. Several other reports of antigen-flagellin
fusion proteins showed both Th1 and Th2 type immune
activation by flagellin in a BALB/c mouse model [34].
Dziadek et al. found that the levels of Th1-type cytokines
and lymphoproliferation were dependent on the vaccine
composition and the genetic background of the mice [35].
Sack et al. also found BALB/c F9(−/Y) mice had a Th2
skewed response and C3H/HeJ F9(−/Y) mice had a mixed
Th1 and Th2 response [36]. Moreover, the cytokine pro-
file in C3H/HeJ females was a mixture of Th1 and Th2
whilst a mainly Th1 profile was observed in C57BL/6
mice during the allogeneic and syngeneic vaccination
against prostate cancer [37]. In our study, both HA1-2-
specific IgG1 and IgG2a titers in the HA1-2-fliC group
were significantly higher than those in the HA1-2
group (Fig. 6b), suggesting that HA1-2-fliC elicits a
higher and more balanced Th1 and Th2 response than
Fig. 6 Immunogenicity of fusion protein. Groups of C3H/HeJ mice (n = 6) were vaccinated i.p. with three doses of HA1-2, HA1-2-fliC, or PBS on
days 0, 14, and 28. The animals were bled 12 days following the second and third immunization. Antibody titers were measured by ELISA or HAI
assay. a HA1-2-specific IgG titers. Serum samples of each group were collected at 12 days post-second and -third immunization (on days 26 and
40). b HA1-2-specific IgG subtype (IgG1, IgG2a) titers. Serum samples of each group were collected at 12 days post-third immunization (on day 40).
c HAI titers. Serum samples of each group were collected at 12 days post-third immunization (on day 40). d The longevity of HA1-2-specific IgG.
Serum samples of each group were collected for 3 months at 12-day intervals after the third immunization (days post-third immunization, d.p.3rd.i).
All Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, *** p < 0.001
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HA1-2 alone in a C3H/HeJ mouse model. Consistent
with our study, C3H/HeJ mice injected with the multi-
meric VLP vaccine showed a strong and long-lasting
immune response against a C-terminal fused epitope
with a balanced Th1/Th2 response [38].
Vaccination that induces long-term immunity is still
regarded as the best means of protection against influenza.
An essential requirement of any vaccine is the induction of
long-term protective immunity [39]. In a previous study,
blood samples of adults were collected on days 0, 7, and 30
after immunization with trivalent inactivated influenza vac-
cine (TIV) or live-attenuated influenza vaccine (LAIV) vac-
cines. In these subjects, the effector IgA and IgG antibody
secreting cell (ASC) responses appeared in the circulation
with a sharp peak around day 7, and quickly disappeared
thereafter (on day 30) [40]. Researchers have also evaluated
the effector response in adults and 5- to 9-year-old children
after TIV immunization (days 27 to 47) and found that very
few subjects had influenza virus-specific IgG ASC [41]. In
our research, the IgG titers induced by HA1-2-fliC
reached the highest levels on day 12 post-final boost, and
the HA1-2-specific IgG titers in these mice remained high,
even on day 84 (Fig. 6d). Our results are similar to those
from an H5N1 influenza virus study in which flagellin-HA
vaccines also elicited robust HAI antibody responses for
3 months [25].
HAI antibody activity remains a World Health Organi-
zation accepted correlate of protection against influenza
[42]. Song et al. found that the STF2R0.HA1-2 (created
by using H5N1 HA1-2 to replace the domain D0 of S.
typhimurium fljB, STF2) construct failed to elicit signifi-
cant levels of serum HAI antibodies following either two
or three immunizations, while STF2R3.HA1-2 (created
by using H5N1 HA1-2 to replace the domain D3 of
STF2) elicited the highest HAI titers with geometric
mean titers of 63 and 35 following three and two immu-
nizations, respectively [15]. Here, the significant HAI
titers (average 54, following three immunizations) that
were elicited by HA1-2-fliC confirmed that it has a higher
immunogenicity than HA1-2 alone (Fig. 6c). Based on
these results, we cautiously predict that the HA1-2-fliC
subunit vaccine could provide effective protection against
H7N9 influenza virus infection.
Recently, it was reported that a Vibrio vulnificus fla-
gellin (FlaB) served as a mucosal adjuvant to enhance
tetanus toxoid-specific antibody responses in both sys-
temic and mucosal compartments [43]. Additionally,
HIV antigen p24 replacement of domains D2 and D3
in non-pathogenic E. coli-derived flagellin (KF) pro-
moted mucosal IgA production, creating a potentially
promising mucosal adjuvant [44]. Based on these intri-
guing findings, our future work will explore the muco-
sal adjuvant activity of S. typhimurium flagellin for
influenza H7N9 vaccine development.
Conclusions
Our study has shown that a HA1-2-fliC recombinant
subunit vaccine was efficiently expressed in an E. coli pro-
karyotic system, and it induced a robust antigen-specific
antibody response that was maintained at maximal levels in
the serum for at least 3 months. This vaccine also induced
a functional antibody response (HAI). In summary, the fliC
fragment of the fusion protein successfully acts as an adju-
vant, and improves the immunogenicity of the recombinant
subunit vaccine, making this a viable strategy for creating
successful H7N9 influenza vaccines.
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